An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Mg0017 50556, Chapel Hill

Mg0017 50086, Charlotte

Mg0017 50076, Columbus

Mg0017 50569, Greenfield

Mg0017 50557, O'Fallon

Mg0017 50555, Austin

Mg0017 50564, Scottsdale

Mg0017 50559, Los Angeles

Mg0017 50593, Rancho Mirage

Mg0017 50099, San Francisco

Mg0017 50304, Dallas

Mg0017 50111, Seattle